[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441881":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":60,"collaborators":38,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":38,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":38,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":38,"overallStatus":43,"whyStopped":38,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Zhongnan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-FAPI PET\u002FCT in malignant tumors","EXPERIMENTAL","Investigators select subjects from patients who have underwent whole-body 18F-FDG PET\u002FCT scan for suspected or confirmed malignancy, or suspected recurrence and metastasis after treatment for malignant tumors, focusing on malignant tumors with low FDG uptake including glioma, hepatocellular carcinoma, renal cancer, gastrointestinal cancer, and peritoneal metastases. Then the subjects receive whole-body 68Ga-FAPI PET\u002FCT scan with time interval of one to four week.",[13,14],"Drug: 68Ga-FAPI","Device: PET\u002FCT",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","68Ga-FAPI","68Ga-FAPI was injected intravenously to each subject, and the dose is calculated according to body weight of subject (approximately 1.85-3.7MBq\u002Fkg).",[9],[22],"68Ga-fibroblast activation protein inhibitor",{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DEVICE","PET\u002FCT","68Ga-FAPI PET\u002FCT scan were performed 20\\~60 min after 68Ga-FAPI (1.85-3.7MBq\u002Fkg) injection intravenously.",[9],[29],"positron emission tomography\u002Fcomputed tomography",[31],{"name":32,"affiliation":5,"role":33},"Yong He, MD, PhD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","+86-27-67812698",null,"vincentheyong@163.com",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Zhongnan Hospital of Wuhan University","RECRUITING","Wuhan","Hubei","430071","China","CN",{"type":50,"coordinates":51},"Point",[52,53],114.26667,30.58333,{"lat":53,"lon":52},[56,59],{"name":57,"role":36,"phone":58,"phoneExt":38,"email":38},"Lei Zheng","+86-27-67812787",{"name":32,"role":33,"phone":38,"phoneExt":38,"email":38},{"type":33,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Yong He","principal investigator","100441881","68ga-fapi-petct-in-malignant-tumors-100441881",false,"NCT05034146","68Ga-FAPI PET\u002FCT in Malignant Tumors","The Diagnostic Efficiency of 68Ga-FAPI PET\u002FCT in Malignant Tumors","Inclusion Criteria:\n\nVolunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor\n\nExclusion Criteria:\n\nFemale patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month",true,"ALL","18 Years","88 Years",{"count":75,"type":76},500,"ESTIMATED","INTERVENTIONAL",[79],"NA","Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms. FAP can be detected in various of malignant neoplasms and is associated to tumor cell migration, invasion, and angiogenesis. Recently, a novel molecular probe, gallium 68-labelled FAP inhibitor (68Ga-FAPI), has been developed and used for visualization of tumor stroma by targeting FAP. Recent studies show favorable diagnosis efficiency in a variety of tumors, especially in gastrointestinal cancer, but the previous studies were all small-sample data or case reports. Therefore, further large-size research is necessary to confirm the advantages of 68Ga-FAPI in various of malignant tumors.",[82,25,83],"Fibroblast Activation Protein Inhibitor","Malignant Neoplasm","2025-05-31",{"date":86,"type":87},"2025-06-05","ACTUAL",{"date":89,"type":87},"2021-02-23",{"date":91,"type":76},"2025-12-31",{"name":5,"class":6},1]